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Malignant astrocytomas are highly aggressive brain tumours with poor prog-
nosis. While a number of structural genomic changes and dysregulation of
signalling pathways in gliomas have been described, the identiﬁcation of bio-
markers and druggable targets remains an important task for novel diagnostic
and therapeutic approaches. Here, we show that the Wnt-speciﬁc secretory
protein Evi (also known as GPR177/Wntless/Sprinter) is overexpressed in astro-
cytic gliomas. Evi/Wls is a core Wnt signalling component and a speciﬁc regulator
of pan-Wnt protein secretion, affecting both canonical and non-canonical signal-
ling. We demonstrate that its depletion in glioma and glioma-derived stem-like
cells led to decreased cell proliferation and apoptosis. Furthermore, Evi/Wls
silencing in glioma cells reduced cell migration and the capacity to form tumours
in vivo. We further show that Evi/Wls overexpression is sufﬁcient to promote
downstream Wnt signalling. Taken together, our study identiﬁes Evi/Wls as an
essential regulator of glioma tumourigenesis, identifying a pathway-speciﬁc
protein trafﬁcking factor as an oncogene and offering novel therapeutic options
to interfere with the aberrant regulation of growth factors at the site of
production.
INTRODUCTION
Malignant astrocytomas are the largest group of primary brain
tumours. Glioblastoma, the most common and most aggressive
form, is characterized by marked cellular heterogeneity, high
proliferative activity, aberrant microvascular proliferation,
presence of necrosis and highly invasive growth (Riemensch-
neider & Reifenberger, 2009). They most commonly arise
de novo (‘primary glioblastoma’) or develop by progression
from pre-existing lower grade tumours (‘secondary glioblas-
toma’) (Ohgaki & Kleihues, 2007; Wettenhall & Smyth, 2004).
Glioblastomas are characterized by complex genetic and
epigenetic aberrations that differ between primary and second-
ary glioblastomas but affect a similar set of pathways, in
particular receptor tyrosine kinase/Ras, phosphoinositol
3-kinase, p53 and pRb signalling (TCGA, 2008). Despite highly
aggressive multimodal therapy, including surgical resection
followed by combined radio- and chemotherapy, the median
survival of glioblastoma patients has remained as low as
12–14 months throughout the past decade (Furnari et al, 2007;
Holland, 2001).
AberrantWntsignallingismolecularlylinkedtomanyhuman
cancers, including colorectal, breast, ovarian, hepatocellular
carcinoma, melanoma and neuroectodermal tumours (Lindvall
Research Article
Evi/Gpr177 in glioma pathogenesis
(1) German Cancer Research Center (DKFZ), Division of Signaling and
Functional Genomics and Heidelberg University, Faculty of Medicine
Mannheim, Department of Cell and Molecular Biology, Heidelberg,
Germany
(2) German Cancer Research Center (DKFZ), Division of Molecular Genetics,
Heidelberg, Germany
(3) German Cancer Research Center (DKFZ), Clinical Cooperation Unit
Neuropathology and Department of Neuropathology, Heidelberg Uni-
versity, Heidelberg, Germany
(4) Division of Neurosurgical Research, Department of Neurosurgery,
Heidelberg University, Heidelberg, Germany
(5) Department of Neuropathology, Heinrich-Heine-University, Du ¨sseldorf,
Germany
*Corresponding author: Tel: þ49 6221 421950; Fax: þ49 2621 421959;
E-mail: m.boutros@dkfz.de
**Corresponding author: Tel: þ49 6221 421955; Fax: þ49 6221 421959;
E-mail: i.augustin@dkfz.de
38  2011 EMBO Molecular Medicine EMBO Mol Med 4, 38–51 www.embomolmed.orget al, 2007; Lustig & Behrens, 2003; Polakis, 2007; Saif & Chu,
2010). Its role has been best characterized in colorectal cancer,
where mutations in the tumour suppressor APC lead to
activation of Wnt signalling. Medulloblastoma arise often in
patients with the Turcot syndrome, a subgroup of which is
genetically characterizedby germline mutations intheAPC gene
(Hamilton et al, 1995). Mutations in other Wnt pathway
members, including b-catenin and Axin2, and aberrant
production of Wnt ligands also have been associated with
cellular transformation and tumour development (Behrens &
Lustig, 2004; Klaus & Birchmeier, 2008; Reya & Clevers, 2005).
Recent results identiﬁed a correlation between aberrant
activation of Wnt/b-catenin signalling and progression in
astrocytoma (Liang et al, 2009; Liu et al, 2010a; Sareddy et
al, 2009). Despite the importance of Wnt signalling in
tumourigenesis, there is still a lack of druggable targets in the
Wnt pathway to modulate its activity and potentially inhibit
tumour growth (Barker & Clevers, 2006).
Wnt proteins are highly conserved secreted, cysteine-rich
glycoproteins. They initiate at least three intracellular signalling
cascades: the canonical/b-catenin-dependent Wnt pathway, the
planar cell polarity (PCP) and the Wnt/Ca
2þ pathway
(McDonald & Silver, 2009). Different Wnt signalling pathways
share several components including receptor complexes and the
adaptor protein Dishevelled (Axelrod et al, 1998; Boutros et al,
1998), but diverge further downstream and control distinct
molecular and physiological outcomes (Cadigan & Peifer, 2009;
Seifert & Mlodzik, 2007).
The molecular mechanisms governing the maturation and
secretion of Wnt ligands in the producing cells are only beginning
to emerge. We previously identiﬁed Evi/Wntless/Sprinter/
GPR177, a highly conserved seven-pass transmembrane protein,
as a component of the Wnt secretion machinery (Banziger et al,
2006; Bartscherer et al, 2006; Goodman et al, 2006). Evi acts as a
Wnt cargo receptor, shuttling between the Golgi and the plasma
membrane and is required for exocytosis of Wnt proteins
(reviewed in Bartscherer & Boutros, 2008; Eaton, 2008). Evi is
essential for Wnt secretion and its loss leads to accumulation of
Wnts in the producing cell (Banziger et al, 2006; Bartscherer et al,
2006). Genetic inactivation of Evi in Drosophila leads to early
embryonic patterning defects that phenocopy Wnt/Wg-depletion.
Loss-of-function of Evi in mice causes embryonic lethality due to
disruption of axial patterning (Fu et al, 2009).
Here, we demonstrate that Evi is overexpressed in human
astrocytic gliomas relative to normal adult brain tissue. Our
experiments show that Evi is required for glioma cell growth
ex vivo and in vivo. Loss of Evi resulted in downregulation of cell
cycle and survival genes. These experiments identify Evi as a
potential molecular marker of human glioma and establish a
functionalroleofEviinthepathogenesisofhumanbraintumours.
RESULTS
Evi is overexpressed in astrocytomas
Evi is ubiquitously expressed during mouse embryonic devel-
opment with particular prominent expression in the developing
headstructures. Expression persistsinadulttissueswithdistinct
expression pattern and levels in different organs (Jin et al, 2010;
Yu et al, 2010; our unpublished data). Evi is essential for Wnt-
dependent developmental processes (Fu et al, 2009). To assess
Evi expression during brain tumourigenesis, we analysed an
expression proﬁling database of 71 diffuse astrocytic tumours of
different malignancy grades [WHO grade II: n¼8; WHO grade
III: n¼11; WHO grade IV (primary glioblastoma: n¼42 and
secondary glioblastoma: n¼10)] (Toedt et al, 2011). Strikingly,
wefoundthatEviisstronglyoverexpressedinastrocyticgliomas
of all malignancy grades as compared to control tissue (Fig 1A).
This ﬁnding was conﬁrmed in an independent data set from the
Molecular Brain Neoplasia Database (REMBRANDT) (Madha-
van et al, 2009), which also revealed a signiﬁcant upregulation
of Evi transcripts in gliomas. Moreover, higher levels of Evi
expression were associated with shorter overall survival of
glioma patients (p¼0.013) (Fig S1 of Supporting information).
Evi expression levels showed no association with gender, age,
TP53, IDH1 or IDH2 mutation status or with MGMT promoter
methylation status (data not shown).
In order to examine the expression of Evi at the protein level,
we raised an antibody against its N-terminus. The antibody
recognized a protein with the expected size of  45kDa, which
was lost or reduced after depletion by siRNA targeting Evi
(Fig 1B). Both Evi #1 and Evi #3 siRNA revealed a strong
reduction of Evi protein and mRNA levels (Fig 1B and C).
Immunoﬂuorescence analysis of U87MG cells revealed strong
perinuclear Evi staining (Fig S2A of Supporting information),
consistent with previous reports from other cell types (Fu et al,
2009; Korkut et al, 2009). Next, we examined Evi protein levels
in normal and astrocytic tumour tissue. In normal brain (NB)
tissue, Evi was restricted to vascular smooth muscle cells,
ependymal cells, few neurons and some astrocytes in NB tissue
(Fig 1D and E). In contrast, and consistent with the mRNA
expression data, Evi protein was highly expressed in tumour
cellsofbothlow-gradeandhigh-gradegliomas(Fig1F–I).Taken
together, our data demonstrates that Evi is strongly over-
expressed in diffuse astrocytic gliomas irrespective of the WHO
grade.
Evi gain-of-function enhances Wnt-reporter-activity
Next, we asked whether Evi overexpression is sufﬁcient to lead
to an increase in Wnt signalling. To this end, we generated Evi
overexpressing embryonic stem cells (ESCs) by targeted
insertion of a C-terminal tagged Evi-YFP into the ROSA26-locus
(Fig S3 of Supporting information). Immunoﬂuorescence
analysis of ROSA26::Evi-YFP ESC conﬁrmed Evi-YFP fusion
protein expression with perinuclear enrichment (Fig 2A).
Quantitative RT-PCR revealed elevated Evi transcription in
ROSA26::Evi-YFP ESCs and Western blot analysis with an
antibody against Evi detected endogenous and Evi-YFP fusion
protein (Fig 2B and C).
We then tested whether overexpression of Evi is sufﬁcient to
induce Wnt signalling activity. As shown in Fig 2D and E, both
ROSA26::Evi-YFP ESCs and Evi transfected HEK293 cells lead to
a higher Wnt reporter activity, indicating that an increase in Evi
levels can lead to overactivation of Wnt signalling pathways.
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In order to analyse the functional role of Evi in glioma cells,
we silenced Evi in glioblastoma cell lines and glioblastoma-
derived cancer stem-like cells. Glioblastoma cell lines
express varying levels of Evi transcripts as determined by qPCR
analysis. Among these, U87MG, A172 and T98G cells showed
the highest level of Evi expression (Fig S2B of Supporting
information).
Evi is an essential Wnt secretion factor for canonical and non-
canonical Wnt ligands. To test the effect of Evi silencing on
Wnt ligand secretion, we examined the ability of conditioned
media from wild-type (WT) and Evi silenced U87MG cells to
induce Wnt reporter activation in HEK293 cells. Depletion
of Evi led to signiﬁcantly reduced Wnt response in HEK293
7TCF ﬁreﬂy luciferase reporter cells (Fig S2C of Supporting
information).
Next, we examined the consequences of Evi silencing on cell
viability in glioblastoma cell lines. Depletion of Evi by RNAi
resultedinsigniﬁcant inhibition ofcellviability inU87MG, A172
and U251MG cells compared to transfections with control
siRNAs, while no change in viability was observed in T98G cells
(Fig 3A and Fig S4A and B of Supporting information). In
contrast, b-catenin silencing only signiﬁcantly affected the
viability of U87MG and U251MG cells, mostly to a lesser extent.
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Figure 1. The Wnt secretion factor Evi is overexpressed in astrocytic gliomas.
A. Log2-geneexpressionratios normalizedtothemean expressionin NBsamples areshownfordiffuseastrocytomaWHOgradeII(AII),anaplastic astrocytoma
WHOgradeIII(AAIII),secondaryglioblastomaWHOgradeIV(sGBIV)andprimaryglioblastoma WHOgradeIV(pGBIV).MedianRNAexpressionisindicatedby
horizontal bars; boxes show the 25th and 75th percentile range, whiskers mark the 5th and 95th percentiles; maximum and minimum values are depicted
as horizontal bars.
B, C. The specificity of the antibody against Evi was confirmed by siRNA silencing of the target protein. U87MG cells were transfected with three-independent
siRNAs to silence Evi. Silencing of gene expression was validated by Western blot and quantified real-time RT-PCR confirming robust downregulation of Evi
expression. b-Actin was detected as loading control. PCR-data are expressed as mean SD of three-independent experiments (
  p<0.01).
D, E. Representativeimmunohistochemical stainings forEviontissue sectionsofNBand astrocytic gliomas ofdifferent WHOgrades. (D)NB, Evi-positivevascular
smooth muscle cells; (E) NB, Evi-positive ependymal cells.
F, G. Evi-positive tumour cells in a diffuse astrocytoma WHO grade II.
H, I. Evi-positive tumour cells in a primary glioblastoma WHO grade IV. Scale bar: 100mm.
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decrease in cell viability upon Evi silencing. Two out the tested
six cell lines (T98G and LN18) were not dependent on Evi for
growth (Fig 3A and Fig S5A and B of Supporting information),
indicating that they might harbour additional growth promoting
aberrations. All Evi-dependent glioblastoma cell lines (except
LN18) are PTEN mutant, however, a synergism between PTEN
andWntsignallingwouldneed furtherconﬁrmation. Toprovide
additional evidence that Evi silencing affects cell survival, we
performed a colony formation assay with U251MG cells.
Downregulation of Evi led to signiﬁcantly fewer colonies
compared to controls (Fig 3B and Fig S4 of Supporting
information). Taken together, we showed that depleting Evi
reduced the viability of four out of six glioblastoma cell lines.
Long-term shRNA-based silencing of Evi expression through
lentiviral transduction similarly led to reduced U87MG cell
viability as observed in the siRNA-based experiments (Figs S4
and S5C of Supporting information). In addition, we analysed
cycle proﬁles of U87MG cells after Evi depletion. Evi RNAi led to
a G1 arrest, indicated by signiﬁcantly increased number of cells
in G1-phase in Evi-silenced cells compared to control shRNA-
silenced cells (53.4% vs. 47.6%) (Fig S5D of Supporting
information). Concomitantly, the number of cells in S-phase
was reduced in Evi silenced cells (6.5% vs. 12.1%). In contrast,
the subG1-fraction of the cells was not signiﬁcantly changed. A
furtherFACS-basedanalysis ofAnnexin V-positive cellsafterEvi
silencing revealed a slight increase in apoptotic cells indicating
that the observed decrease in cell viability was primarily due to
decreased proliferation but also affects cell death (Fig S5E of
Supporting information). Therefore, we conclude that Evi
predominantly is required for cell proliferation and viability
of glioblastoma cells.
Evi silencing induces apoptosis in stem-like glioma cells
We next analysed whether Evi is required for proliferation and
survival in primary stem-like glioma cells (SLGCs) obtained
from patient-derived glioblastoma samples. Previous studies
have shown that spheroid-forming cells isolated from human
glioblastomas and cultured under serum-free conditions
were enriched for glioma cancer stem cells (Wan et al, 2010).
We tested two SLGC lines (NCH421k and NCH644) which are
derived from a subpopulation of glioma tumour cells that are
Research Article
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Figure 2. Evi overexpressing ESCs showed increased Wnt response.
A. Immunofluorescence of endogeneous expression of Evi-YFP in ESC colonies.
B. Relative mRNA expression levels of Evi were analysed by quantitative RT-PCR. Evi-ESCs expressed increased Evi levels.
C. Western blot of Evi overexpressing ESCs. Evi-ESCs expressed Evi-YFP fusion protein.
D. Evi-ESCs stably transfected with 7TCF Firefly luciferase reporter showed increased Wnt reporter activity (
 p<0.05).
E. Transfection of 7TCF Firefly luciferase reporter containing HEK293 cells with Evi-GFP plasmid led to increased Wnt reporter activity compared to transfection
with GFP control vector (
  p<0.01).
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xenograph transplantation (Campos et al, 2010).
Light microscopic analysis of SLGC spheres transduced with
Evi shRNA versus control shRNA revealed strong morphological
differences: Evi silenced spheres were signiﬁcantly smaller and
lost their packed condensed morphology compared to control
spheres (Fig 4A and Fig S4 of Supporting information).
Moreover, the amount of viable cells was signiﬁcantly reduced
in Evi depleted spheroid cultures (Fig 4B). Further analysis of
apoptotic cells after Evi shRNA transduction revealed an
increase in apoptosis as demonstrated by a signiﬁcant rise in
the sub-G1 fraction with no signiﬁcant changes in cell cycle
distribution(Fig4CandD).Theseexperimentsdemonstratethat
Evi is required for cell survival in primary patient-derived
glioblastoma cells.
Effect of Evi depletion in U87MG on tumour cell migration
and in vivo tumour growth
Glioblastoma are characterized by pronounced invasion of
tumour cells into the surrounding healthy tissue (Tysnes &
Mahesparan, 2001). To examine the consequences of Evi
depletion in glioma cells on cell migration, we performed
transwell migration experiments. As shown in Fig 5A and B,
siRNA-based silencing of Evi expression caused a 32%
inhibition of migration of glioma cells; a more robust lentiviral
shRNA-induced downregulation of Evi led to an even stronger
63% decrease in migratory behaviour.
We then examined the effect of Evi silencing on glioma
tumourigenesis in vivo by comparing the growth of subcuta-
neously grafted control and Evi shRNA transduced U87MG
tumours. Correlating with the reduced proliferative and
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Figure 3. Evi is required for proliferation and
survival of glioblastoma cell lines.
A. Viability of RNAi transduced U87MG cells, A172,
U251MG cells and T98G was determined by
CellTiter-Glow assay and revealed reduced via-
bility of Evi-RNAi transduced cells compared to
control cells. b-catenin silencing had significant
effect on viability of U787MG and U251MG cells.
Evi and b-catenin silencing had no significant
effect on proliferation of T98G cells (
 p<0.05).
B. Eviandb-cateninsilencingcausedreducedcolony
formation in U251MG cells. Representative
example of three-independent experiments is
shown (right). Data are expressed as mean SD
of three-independent experiments (
 p<0.05).
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shRNA-based downregulation of Evi caused a signiﬁcant
reduction of glioma tumourigenesis (Fig 5C). Silencing of Evi
induced a delay in the onset of tumour growth indicating that
depletion of Evi affected growth and survival of glioblastoma
cells after xenotransplantation. Median tumour take time point
of the control cells is 7 days in contrast to 20 days after injection
of Evi silenced cells. Our experiments showed that Evi interferes
with tumour-promoting characteristics like tumour cell migra-
tion and tumour initiation.
Silencing of Evi leads to downregulation of pro-proliferative
genes and interleukins in glioma cells
To identify genes that are transcriptionally controlled by Evi, we
compared expression proﬁles of glioma cells after transfection
withtwo-independent Evi(siRNA Evi#1and Evi#3) andcontrol
siRNAs (Fig 6A). In addition, we performed expression proﬁling
after b-catenin silencing in order to subselect genes regulated
through a canonical Wnt pathway (Fig 6A).
The global expression proﬁles after Evi RNAi were highly
similarforthetwoEvisiRNAs(R
2¼0.99)(FigS6AofSupporting
information), without obvious off-target effects. However,
b-catenin silencing revealed little overlap in expression patterns
compared to Evi depletion, suggesting that Evi silencing affects
primarily the non-canonical/b-catenin-independent Wnt signal-
ling branch in glioma cells. In total, we identiﬁed 139
differentially expressed genes between Evi RNAi and control
treatments with a log odds ratio >10. Thirty genes displayed a
log2-fold change  1.5 (Fig S6B of Supporting information). An
analysis of the differential expression data at the level of KEGG
categories revealed that Evi depletion strongly affected the
expression of genes involved in cell cycle regulation, DNA
replication, mismatch repair and nucleotide excision repair,
among others (Fig 6B). Quantitative RT-PCR conﬁrmed the
regulation of c-Myc, cyclin D1, PTMA and tenascin-C by Evi
(Fig 6C). Since loss-of Evi can affect the production of both
canonical and non-canonical Wnt pathways, we also tested
whether these genes were downregulated after silencing of
b-catenin. As shown in Fig 6, b-catenin silencing reduced PTMA
expression.
Members of the interleukin family including IL8, IL6, IL1B
and IL11 were strongly downregulated after Evi depletion (Fig
6A and C and Fig S6 of Supporting information). Experiments
with conditioned medium of parental U87MG cells rescued the
downregulation of IL6 and IL8 after Evi silencing (Fig S7A of
Supporting information). Similarly the viability effect of Evi
depletion was abolished in the presence of conditioned medium
(Fig S7B of Supporting information). High levels of IL6 and IL8
Research Article
Iris Augustin et al.
D 
A
r
e
l
.
 
c
o
u
n
t
s
 
i
n
 
s
u
b
G
1
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
control
Evi
c
o
u
n
t
PI-A
50 100 150
x 1000
1
0
0
2
0
0
3
0
0
4
0
0
5
0
0
6
0
0
control shRNA
1
0
0
2
0
0
3
0
0
4
0
0
c
o
u
n
t
PI-A
50 100 150
x 1000
Evi shRNA
shRNA
NCH421k
control shRNA Evi shRNA
G1sub = 1.1 
G1 = 78.1 
S = 4.4 
G2 = 16.2 
G1sub = 7.9 
G1 = 76.0 
S = 3.7  
G2 = 12.2 
B 
*
NCH421k NCH644
NCH421k C 
0 
0.5 
1 
r
e
l
.
 
c
e
l
l
 
n
u
m
b
e
r
 
 
 
**
control
Evi
0 
0.5 
1 
***
control
Evi
shRNA
NCH421k NCH644
r
e
l
.
 
c
o
u
n
t
s
 
i
n
 
s
u
b
G
1
 
0 
1 
2 
3 
0.5 
1.5
2.5
control
Evi shRNA
*
r
e
l
.
 
c
e
l
l
 
n
u
m
b
e
r
 
shRNA
Figure 4. Depletion of Evi induces apoptosis in glioblastoma-derived cancer stem-like cells.
A. Neurosphere shape and size was disturbed after Evi silencing. Scale bar: 100mm.
B. Reduction in cell number compared to control transfected spheres 7 days after infection (
  p<0.01;
   p<0.001).
C. Lentiviral shRNA silencing of Evi expression in NCH421k and NCH644 cells led to an increase in the sub-G1 fraction (
 p<0.05;
  p<0.01).
D. Representative graphs of cell cycle distribution. Data are expressed as mean SD of three-independent experiments.
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many cancer types, including glioblastoma (Hodge et al, 2005;
Putoczki & Ernst, 2010; Samaras et al, 2009), however, little is
known on how their expression is regulated. Recently, it has
been shown that IL8 is a target gene of STAT3 in human
glioblastoma cells (de la Iglesia et al, 2008a). Phosphorylated
STAT3 directly binds to the IL8 promotor and inhibits IL8
transcription (de la Iglesia et al, 2008b). Therefore, we analysed
the STAT3 status after Evi silencing compared to control
transfected U87MG cells. Our data showed that Evi depletion
increased phosphorylated STAT3 indicating that STAT3 activa-
tion is downstream of Evi and Wnt secretion (Fig 7A). Taken
together, these results suggest that Wnt proteins regulate IL8
expression via the inhibition of STAT3 phophorylation (Fig 7B).
DISCUSSION
Despite recent advances in surgery and adjuvant therapy, the
overall prognosis for patients with malignant brain tumours
remains poor, emphasizing the need for an in-depth under-
standing of the molecular pathogenesis and the development of
new concepts for cancer therapy. Aberrant activation of Wnt
signalling is important in a variety of human cancers. In this
study, we show that the Wnt-speciﬁc secretion factor Evi is
highly overexpressed in brain tumours, indicating that the
aberrant release of canonical and non-canonical Wnt is a
potential driver of glioma tumourigenesis.
Wnt signalling and its contributions to tumourigenesis have
been characterized in many tissues (Klaus& Birchmeier, 2008;
Polakis, 2007; Reya and Clevers, 2005). For example,
mutations in APC in colon cancer lead to the stabilization
of b-catenin and subsequent increased expression of tran-
scriptional target genes. Aberrant expression of Wnt proteins
has also been implicated in tumour formation, including
breast cancer (Baﬁco et al, 2004; Curtin and Lorenzi, 2010).
Several antagonists have been identiﬁed that target different
components in the Wnt pathway, including blocking protein–
protein interaction of Fz and Dsh at the membrane, b-catenin
and TCF in the nucleus, small molecule inhibitors of
T a n k y r a s e sl e a d i n gt oa ni n c r e a s ei nA x i nl e v e l sa n d
antibodies against Dkk1 and LRP6, however, antagonists
(and agonists) have not yet entered clinical development,
making the Wnt pathway one of the few major signalling
routes which are not yet addressable by targeted therapeutics
(reviewed in Barker & Clevers, 2006; Takahashi-Yanaga &
Kahn, 2010; Liu et al, 2009).
Evi as a potential ‘druggable’ target is one of the most
‘upstream’ core components of the Wnt signalling pathway and
is required for the export of Wnts ligands. Originally, the GPCR-
like transmembrane protein Evi was identiﬁed in a genetic
screen in Drosophila as an essential and speciﬁc component for
Wg export. In vertebrates, it has been shown that Evi binds to
and is required for the release of Wnt1, Wnt3 and Wnt5a (Fu
et al, 2009). Since only a single gene exists in vertebrate as well
as in invertebrate genomes (in contrast to most other Wnt
pathway components), Evi is believed to be involved in the
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tumour formation in xenograft models.
A. Evi shRNA U87MG cells showed less transwell migration compared to
control. Similar effect was achieved by siRNA transfection.
B. Migration experiments were done as short-term assays to exclude anti-
proliferative effects. Values represent mean SD from three-independent
experiments (
 p<0.05;
  p<0.01).
C. Reduced in vivo growth of glioma cells transfected with shRNA targeting
Evi. The appearance of U87MG glioma xenografts formed by Evi shRNA or
control transfected cells was reduced in the Evi downregulated glioma
cells.
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A. Heatmap based on normalized U87MG gene expression values of RNAi Evi#1, Evi#3, b-catenin and control samples. Rows represent genes, which are
differentially expressed (p<0.01) and have an absolute log2-fold change >1.5 compared to control, in Evi#1, Evi#3 or b-catenin silencing experiments.
B. Over-represented KEGG categories in set of differentially expressed genes (Fisher’s exact test, p<0.01). The length of the bars represents the number of genes
within the set of differentially expressed genes that are annotated as part of the corresponding KEGG category. The numbers is red indicate the significance of
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analysed by quantified RT-PCR. Data are expressed as mean SD of three-independent experiments.
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canonical Wnt ligands (Gordon & Nusse, 2006; van Amerongen
& Nusse, 2009). These properties make Evi an interesting target
for modulating aberrant Wnt signalling at the source of
production.
We found that Evi expression is upregulated in human
astrocytic glioma tissues of different WHO grades when
compared to NB tissue. In diffuse astrocytomas WHO grade
II, Evi expression was strongly increased and remained at high
levels in anaplastic astrocytomas WHO grade III and glioblas-
tomas WHO grade IV, indicating that high-levels of Evi may be
required for early neoplastic transformation. This also points
towards the secretion of Wnt ligands as the limiting step of the
signalling cascade in cancerous brain tissues, rendering
increased expression of the Wnt cargo-receptor Evi essential
for both tumour initiation and tumour growth. Indeed, previous
studies showed upregulation in brain tumours of both canonical
and non-canonical Wnt signalling components including Wnt1,
Wnt2 and Wnt5a (Liu etal, 2010c; Pu et al, 2009; Yu et al, 2007).
In glioma cell lines, such as U87MG, non-canonical Wnt5a is the
most abundant Wnt ligand (Fig S8 of Supporting information,
Kamino et al, 2011). Wnt5a has oncogenic and anti-oncogenic
properties, depending on the tumour type. In colorectal cancer,
for example, Wnt5a has tumour suppressive function (Dejmek
et al, 2005). For brain tumours it has been reported that Wnt5a
stimulates cell motility and inﬁltrative activity of tumour cells.
Moreover, Wnt5a expression correlates with brain malignancy
(Kamino et al, 2011). In addition it has been shown that Wnt-
driven PCP signalling suppresses endothelial cell proliferation
and migration supporting tumour promoting function of non-
canonical Wnt signalling cascades (Ju et al, 2010). Further
studies will be required to identify the Wnt ligands that are
inﬂuenced by the upregulation of Evi. Since glioblastoma cell
lines and tumour specimens express both canonical and non-
canonical Wnt, it is tempting to speculate the modulation of Evi
might disturb a ﬁnely tuned balance between canonical and
non-canonical signalling required for homoestasis. While Evi
has been shown to have speciﬁc phenotypes in Wnt signalling,
at this stage it cannot be excluded that it inﬂuences additional
processes in glioma.
Ex vivo experiments revealed that loss-of Evi in different
glioblastoma cell lines and glioblastoma derived cancer stem-
like cultures affected cell proliferation, migration and apoptotic
cell death. The requirement of Evi for glioblastoma cell survival
was further conﬁrmed by the observed reduced tumourigenesis
in xenograft models. Furthermore, the inhibition of cell
proliferation after Evi silencing in glioblastoma cell lines was
accompanied by cell cycle arrest in G1. However, not all
glioblastoma cell lines are dependent on Evi. This ﬁnding is
currently mechanistically not understood.
Evi depletion interferes with the cell cycle progression. C-myc
and cyclin D1 genes are associated with tumour proliferation
and previous studies identiﬁed that cyclin D1 regulates G1-to-S
phase transition (Liu et al, 2010c). The nuclear oncogenic
protein PTMA is involved in cell proliferation but also in
apoptosis (Letsas & Frangou-Lazaridis, 2006). PTMA expression
is also positively regulated by the transcription factor c-myc,
indicating that downregulation of c-myc by Evi depletion may
contribute to reduced PTMA expression. Like other oncopro-
teins, tenascin-C overexpression correlates with a variety of
cancer types and tumour cell lines. Tenascin-C is an extra-
cellular matrix molecule, which modulates adhesion and is
highly expressed in the microenvironment of most solid
tumours. High tenascin-C expression correlates with malig-
nancy in astrocytic tumours and has been associated with less
favourable prognosis (Orend & Chiquet-Ehrismann, 2006).
Previous studies revealed that tenascin-C expression is asso-
ciated with proliferation and invasiveness of tumour cells.
Reduced tenascin-C expression after Evi silencing might
contribute to less mobility and invasion of Evi targeted tumour
cells.
Expression proﬁling analysis of U87MG cells after Evi
silencing revealed a strong reduction in transcription of several
interleukin genes. Signalling functions of IL6 and IL8 have been
implicated in glioma stimulating both cell survival and tumour
growth. High expression of IL6 and IL8 was found to be
associated with glioma malignancy through promotion of
proliferation, survival and invasiveness (Hodge et al, 2005;
Liu et al, 2010b; Putoczki & Ernst, 2010; Samaras et al, 2009).
Evi overexpression leads to an increase in Wnt response likely
due to an increased Wnt secretion, suggesting that enhanced
Wnt signalling stimulates tumour cell growth possibly by
upregulation of interleukins and other pro-oncogenic factors.
We found that b-catenin silencing has no signiﬁcant effect on
interleukin expression, suggesting that b-catenin-independent
Wnt signalling is important for transcriptional regulation of
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Figure 7. Downregulation of Evi repressed IL transcription by activation
of STAT3.
A. Western blot of U87MG cell lysates after RNAi transfection against Evi (Evi
#1 and Evi #3) showed increased levels of phosphorylated STAT3 com-
pared to control transfection. b-Actin was detected as loading control.
Representative example of three-independent experiments is shown.
B. Model of the Evi-Wnt-STAT3-IL8 signalling link in human glioblastoma
cells. Evi mediated Wnt secretion controls phosphorylation of STAT3.
Downregulation of Evi leads to activation of STAT3 by phosphorylation.
Phosphorylated STAT3 binds to IL8 promotor and represses IL8 tran-
scription. Downregulation of IL8 reduces glioblastoma cell proliferation
and invasiveness.
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in PTEN-mutated glioblastoma cell lines (de la Iglesia et al,
2009). The identiﬁcation of Evi and Wnt secretion as a novel
regulator of STAT3 activation in glioma cells might deﬁne a new
connection between Wnt signalling and IL8 production affecting
tumour cell growth (Fig 7B). Recent results showed that the
chemokine receptor CXCR7 is highly expressed in glioma and is
probably required for directionality of cell migration (Hatter-
mann et al, 2010). Our expression analysis revealed that
silencing of Evi signiﬁcantly increased CXCR7 expression.
Previous studies suggested that signalling events downstream
of CXCR7 include an activation of Jak2/STAT3 as well as
MAPK pathways (Gao et al, 2007). Therefore, we hypothesize
that Evi might control STAT3 phosphorylation via CXCR7
expression.
Together, our data demonstrate that Evi-mediated Wnt
signalling regulates proliferation, survival and migration of
glioma cells, which are critical aspects of the pathogenesis
of human brain tumours. Our study also shows for the ﬁrst
time that upregulation of a growth-factor speciﬁc secretory
proteins can contribute to tumourigenesis, indicating that
the Wnt cargo-receptor might be a limiting factor in situations
when Wnt proteins are overexpressed. Targeting Evi may
represent a potential strategy for therapeutic intervention
as its inhibition affects multiple Wnts and would limit
overactivation of both canonical and non-canonical Wnt
signalling.
MATERIALS AND METHODS
Construct of the Evi targeting vector
For expression of Evi as a C-terminal tagged Evi-GFP fusion protein,
human and mouse Evi cDNA was cloned into pEGFP-N1 expression
vector. The coding sequence was cloned into EcoRI and BamHI
sites. The gene-targeting ROSA26-b-geo construct used to target
WT ESCs by homologous recombination was generated based on
constructs published by Soriano, 1999. The conditional Evi-
construct was integrated into the first XbaI-site after exon 1 of
the ROSA26 gene. The flanking genomic sequence (1.1kb 50-prime
arm and 4.3kb 30-prime arm) between two EcoRV-sites was cloned
in the targeting vector and used for homologous recombination.
We generated the ROSA26::Evi-YFP ESC line by loxP gene targeting
and Cre-mediated deletion of the b-geo-cassette. Genotyping was
done with the following primer pairs: WT: gtcgctctgagttgttatcag,
ccagatgactacctatcctcc; Evi floxed: gtcgctctgagttgttatcag, gacgacag-
tatcggcctcaggaag.
Cell lines and tumour models
Human glioblastoma cell lines U87MG, A172, T98G, U251MG, LN18
and LN229 cell lines were kindly provided by Dr. W. Roth and Dr. P.
Angel (DKFZ). Cells were grown as monolayers in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% foetal bovine serum (Invitrogen) at
378C and 5% CO2 in a humidified atmosphere. The investigated
glioma stem-like cell line NCH421k and NCH644 were previously
established from a primary glioblastoma patient undergoing surgical
resection as approved by the Institutional Review Board at the Medical
Faculty, University of Heidelberg. This cell line was genotyped and
phenotypically characterized (Campos et al, 2010). NCH421k and
NCH644 were cultivated at 378C in a humidified incubator with 5%
CO2 as floating aggregates (neurospheres) on uncoated tissue culture
dishes. Glioma stem-like cell medium consisted of Dulbecco’s modified
Eagle medium/F-12 medium containing 20% BIT serum-free supple-
ment, basic fibroblast growth factor (bFGF) and epidermal growth
factor (EGF) at a concentration of 20ng/ml each (all Provitro, Berlin,
Germany).
Mouse ESCs were cultured on mouse embryonic fibroblasts or
gelatine-coated dishes in DMEM containing 15% FCS, 2mM L-
glutamin, MEM non-essential amino acids, 1mM MEM sodium
pyruvate, 100mM b-mercaptoethanol and 1000U/ml LIF (Millipore).
Cells were routinely splitted every second day.
Mission RNAi clones targeting Evi were obtained from Sigma–Aldrich
(TRCN0000133858 [Evi shRNA#1], TRCN0000138901 [Evi
shRNA#2], TRCN0000138525 [Evi shRNA#3], Mission Non-Target
shRNA Control Vector). pCF826:pLenti 7xTCF Firefly luciferase//
SV40-PuroR (TCF luciferase reporter) construct was kindly provided
by Roel Nusse (Fuerer & Nusse, 2010). Lentiviral particles were
produced according to the manufacturer’s instruction (Sigma–Aldrich).
Produced lentiviruses were concentrated by ultra centrifugation using
SW41 rotor (Beckman Coulter, Fullerton, CA, USA). Titer was
measured by detecting GFP positive HEK293T cells using flow
cytometry. Before transduction, neurospheres were dissociated by
trypsinization. Transductions were performed at five of multiplicity of
infection (MOI 5), conferring  90% transduction efficiency without
significant cytotoxicity in negative control samples. Stable infected
glioblastoma cell lines were selected in a medium containing 1mg/ml
puromycin (Invitrogen). Stable cell lines were maintained as polyclonal
cell populations. Transient siRNA transfections of all cell lines were
conducted using Dharmafect Reagent (ThermoFisher). siRNAs
against human Evi, b-catenin and control siRNAs had the targeting
sequences:
ACGAAUCCCUUCUACAGUA ðEvi#1Þ
UAACGGAAGGCCAUUGGAA ðEvi#2Þ
UAAAGGAUAUCCGGUUGGU ðEvi#3Þ
Pool of GCUGAAACAUGCAGUUGUA, GAUAAAGGCUACUGUUGGA, CCA-
CUAAUGUCCAGCGUUU, ACAAGUAGCUGAUAUUGAU (b-catenin) and
P002070-01-20 (control).
Cells were transfected in 384-, 24- or 6-well plates using 20nM
siRNA. siRNA transfected cells were cultured for 3 days prior to use for
immunocytochemistry, Western blot and qPCR experiments.
Cell proliferation, colony forming assay and transwell
migration assay
To assess cell viability, 500 cells were plated in quadruplicates in 384-
well plates and viability was measured at different time points using
CellTiter-Glo (Promega) according to the manufacturer’s protocol. For
rescue experiments, the medium of siRNA-transduced cells was daily
changed against conditioned medium obtained from parental U87MG
cells. Evi-YFP ESC and HEK293 T7 TCF firefly luciferase reporter cells
were used for the Wnt-reporter assays. Luciferase assay was
performed 2 days after seeding of the cells or adding conditioned
medium to the Wnt reporter cells. Reporter activity was normalized to
cell viability (CTG assay).
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transfected with siRNA. After 2 days 1000 cells per 6-well were plated
in triplicates and incubated for 2 weeks before they were stained with
0.1% crystal violet. For migration assays, invasion chambers (Corning)
were used according to the manufacturer’s instructions. Briefly,
uncoated transwell membrane filter inserts (6.5mm in diameter,
8-mm pore size and 10-mm-thick polycarbonate membrane) were
placed in a 24-well tissue culture plates. Cells (1 10
5) suspended in
DMEM containing 10% serum were pipetted in duplicate into the top
chambers and DMEM containing 10% FBS was added to each bottom
chamber. After 16h incubation at 378C, non-migrating cells were
removed from the upper face of the filter using cotton swabs and cells
on the lower filter surface were fixed and stained with haematoxylin
(Sigma). The number of cells per microscopic field was counted light
microscopically. The average number of migrating cells within seven
random fields was calculated.
Western blotting
Cell pellets were dissolved in lysis buffer containing 8M urea, 0.1M
NaH2PO4, 10mM Tris–HCl. Cell pellets used for detection of
phosphorylated STAT3 were lysed in same buffer with additional
phosphatase inhibitors (Roche). Lysates were incubated on ice for
10min and the centrifuged at maximum speed for 20min. The
supernatants were collected and protein concentrations were
determined by BCA method. Protein (10–30mg) was separated on
4–12% NuPage gradient gels and transferred to PVDF-membranes.
Membranes were blocked and incubated overnight at 48Co r1ha tR T
with one of the following antibodies: anti-Evi (1:500, rabbit) and anti-
b-catenin (1:1000, mouse, BD Transduction Laboratories #610154).
Blots were then incubated with corresponding horseradish perox-
idase-conjugated secondary antibodies (1:10000; Sigma). To confirm
equal loading of the proteins, the blots were also immunoprobed with
a mouse monoclonal antibody against b-actin (1:1000000; Sigma).
The antiserum against Evi was generated against the peptide
FTSPKTPEHEGRYYNC of the first extracellular loop.
Immunohistochemistry and cytochemistry
Non-neoplastic tissue samples from autopsy brains and human
tumour tissues from neurosurgical biopsy samples were obtained from
the Department for Neuropathology, Institute for Pathology, University
of Heidelberg. All samples were analysed in an anonymized manner as
approved by the local institutional ethics boards. In total, immuno-
histochemistry was carried out on 16 tumours (4 diffuse astrocytomas
WHO grade II, 4 anaplastic astrocytomas WHO grade III and
8 glioblastomas WHO grade IV) and 3 NB tissue samples. Immuno-
histochemical studies were performed on formalin-fixed and paraffin-
embedded specimen. Briefly, sections were deparaffinized in xylene
and passed through graded alcohols and further rehydrated in
phosphate buffered saline (PBS). Antigen unmasking was carried out
by microwaving the sections for 10min in 10mM citrate buffer
(pH 6.0). Sections were then treated with 1%H2O2 for 30min to block
endogenous peroxidase followed by incubation with Avidin/Biotin
blocking solution (Vector) for 1h at RT in a humid chamber. The
sections were then incubated overnight at 48Cw i t hp r i m a r y
antibodies against Evi (1:200). Peroxidase-conjugated secondary
antibody (1:200, Dako) was used for 1h incubation time at RT
followed by 30min incubation with AB-complex. Diaminobenzidine
(DAB) in buffer was used until sections developed colour. Sections were
then counterstained using haematoxylin. Negative control experi-
ments included omission of the primary antibody.
For immunocytochemistry, siRNA transfected U87MG cells were fixed
in 4% PFA/PBS for 10min at RT. After washing steps, blocking was
done with 1% BSA–PBS for 30min. The primary antibody (1:200)
against Evi was incubated overnight at 48C. Fluorescein isothiocya-
nate (FITC)-labelled secondary antibody (1:800) was added for 1h at
RT. ESCs were seeded on glass slides without feeder cells. After fixation
with 4%PFA/PBS nuclei were counterstained with Hoechst dye. Images
were taken with a ZEISS LSM 510 META Confocal Microscope at 63 
magnification.
Flow cytometry
Lentivirally shRNA transduced U87MG, NCH421k and NCH466 cells
were cultured for 16h (U87MG, 20% confluence) or 7 days (NCH421k
and NCH644) prior to analysis. Cells were harvested and stained with
200mg/ml propidium iodide, 0.1% NaAzide and 0.1% Triton X-100,
10mg/ml RNAses for 3h. A total of 20,000 nuclei were examined by
FACS Array (BD Bioscience). AnnexinV staining was performed 6 days
after siRNA transfection with Annexin-V-Alexa 568 staining kit (Roche)
according to the protocol.
Real-time transcription (RT)-PCR analysis
Total RNA was extracted using RNeasy extraction kit (Qiagen)
according to the manufacturer’s instructions. Reverse transcription
and quantitative PCR was performed with 25ng cDNA and
LightCycler 480 Probes Master as described (Roche). Relative mRNA
expression was calculated as a fold-change versus control. For
calculation of Evi copy number, a purified Evi cDNA fragment was
titrated and analysed by quantitative PCR in parallel with cellular
cDNA samples.
Primer sequences:
Evi/Gpr177: F: TCATGGTATTTCAGGTGTTTCG, R: GCATGAGGAACTT-
GAACCTAAAA (probe #38, Roche).
b-Catenin: F: AGCTGACCAGCTCTCTCTTCA, R: CCAATATCAAGTCCAAGAT-
CAGC (probe#21, Roche).
Cyclin D1: F: GAAGATCGTCGCCACCTG, R: GACCTCCTCCTCGCACTTCT
(probe #67, Roche).
C-myc: F: CACCAGCAGCGACTCTGA, R: GATCCAGACTCTGACCTTTTGC
(probe #34, Roche).
PTMA: F: CCTGCTAACGGGAATGCTAA, R: CTTCCTCTTCTTCGTCTACCTCA
(probe #75, Roche).
IL-8: F: ATGGTTCCTTCCGGTGGT, R: AGACAGCAGAGCACACAAGC (probe
#72, Roche).
Expression profiling of human glioma tissue samples
RNA expression of Evi in NB and tumour samples relative to human
reference RNA (Stratagene, La Jolla, USA) was determined using
microarray analysis as described (Toedt et al, 2011).
Expression profiling of Evi silencing experiments
RNA was extracted from two biological replicates of cells transfected
with either Evi siRNA#1, Evi siRNA#3, b-catenin or control. The
poly(A)
þ fraction was isolated from each of the eight samples and used
to probe an IlluminaHumanHT-12 v4 beadchip. These arrays have on
average 15 beads per probe and cover more than 47,000 transcripts
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samples (R
2 of all normalized replicates >0.98). Using BeadStudio
software (v3.2þ), summary intensities for each bead type on the array
were produced, and quantile normalization between samples was
performed. The limma package (v 3.2.1), part of the Bioconductor
package suite, was employed to test for differential expression
(Wettenhall & Smyth, 2004). This test assumes a linear model for
gene expression levels. The differential expression test between both
Evi and control samples is based on the null hypothesis that the
expression values of a gene in the samples come from the same
distribution, and results in p-values for each gene and sample pair.
Specifically, a simple design matrix was formed to fit a linear model to
each gene expression value, where the coefficients corresponded to
the RNA sources of interest (i.e. siRNA Evi #1, Evi #3 and control).
Contrast of interest extracted from the fit where: (1) genes which
respond to knockdown using siRNA Evi #1; (2) genes which respond to
knockdown using Evi #3; (3) genes which respond similarly in both
the knockdowns using siRNA Evi #1 and Evi #3. Data from the latter
contrast is presented in this study. An empirical Bayes method was
used to moderate standard errors and estimate log fold-change from
the data, and a moderated t-statistic was used to assess differential
expression. Genes which had an adjusted (Benjamini–Hochberg)
p-value<0.01 with respect to the third contrast listed above were
regarded as differentially expressed, and used for further KEGG
pathway analysis. Bioconductor GOStats (v2.14), Category (v2.12) and
KEGG.db (v2.14) packages were used to perform a Fisher’s exact test
KEGG categories for over-representation in this gene set. Expression
profiling data is available through ArrayExpress (Acc No: E-MTAB-776).
Statistical analysis
Unless otherwise indicated,d a t aa r ee x p r e s s e da sm e a n  SD.
Statistical significance was calculated by two-tailed Student’s t-test
with unequal variance. A p-value of less than 0.05 was considered
statistically significant and marked by asterisks. Two asterisks
represent p-values of less than 0.01. Three asterisks represent
p-values of less than 0.001.
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The paper explained
PROBLEM:
Malignant gliomas are the most common and most malignant
primary brain tumours in adults and associated with poor
prognosis. Recent evidence supports the involvement of
canonical and non-canonical Wnt signalling in glioma devel-
opment and malignant progression. However, insights into the
mechanism behind Wnt signalling in glioma and the identifi-
cation of druggable targets that can be addressed to inhibit both
signalling branches have been lacking.
RESULTS:
We here describe strong, WHO grade-independent overexpres-
sion of Evi/Wls/GPR177 in human astrocytic glioma suggesting
an involvement of Evi in the earliest stages of glioma
tumourigenesis. Evi/GPR177 is an essential Wnt ligand secretion
factors. Depletion of Evi expression by RNAi in glioma cells and
primary glioblastoma-derived cancer stem-like cells led to
reduced proliferation, cell cycle arrest and increased apoptosis.
Correspondingly, transcriptome profiling identified a strong
transcriptional downregulation of interleukins and genes
associatedwithcellcycleregulationafterEvisilencing.Migration
experiments revealed a reduced capacity for migration of glioma
cells upon Evi silencing and Evi depletion also reduced
tumour growth of human glioma cells after xenotransplantation
in mice.
IMPACT:
Our data established a functional role of Evi/GPR177 in the
molecular pathogenesis of human astrocytic gliomas. Evi
regulates both canonical and non-canonical Wnt signalling in
glioma cells with both branches likely contributing to malig-
nancy. With its GPCR-like structural features Evi may serve an
attractive novel target for therapeutic interventions.
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